JP5873332B2 - 新規化合物および方法 - Google Patents

新規化合物および方法 Download PDF

Info

Publication number
JP5873332B2
JP5873332B2 JP2011519185A JP2011519185A JP5873332B2 JP 5873332 B2 JP5873332 B2 JP 5873332B2 JP 2011519185 A JP2011519185 A JP 2011519185A JP 2011519185 A JP2011519185 A JP 2011519185A JP 5873332 B2 JP5873332 B2 JP 5873332B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
sequence
rv3616c
tuberculosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011519185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528895A (ja
JP2011528895A5 (enExample
Inventor
ブラウン，ジェームズ
メッテンス，パスカル
マーフィー，デニス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2011528895A publication Critical patent/JP2011528895A/ja
Publication of JP2011528895A5 publication Critical patent/JP2011528895A5/ja
Application granted granted Critical
Publication of JP5873332B2 publication Critical patent/JP5873332B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
JP2011519185A 2008-07-25 2009-07-24 新規化合物および方法 Expired - Fee Related JP5873332B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25
US61/083,720 2008-07-25
PCT/EP2009/059580 WO2010010177A1 (en) 2008-07-25 2009-07-24 Novel compositions and methods

Publications (3)

Publication Number Publication Date
JP2011528895A JP2011528895A (ja) 2011-12-01
JP2011528895A5 JP2011528895A5 (enExample) 2012-09-06
JP5873332B2 true JP5873332B2 (ja) 2016-03-01

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011519185A Expired - Fee Related JP5873332B2 (ja) 2008-07-25 2009-07-24 新規化合物および方法

Country Status (24)

Country Link
US (2) US20110117119A1 (enExample)
EP (1) EP2315773B1 (enExample)
JP (1) JP5873332B2 (enExample)
KR (1) KR20110044883A (enExample)
CN (1) CN102164952B (enExample)
AU (1) AU2009273130B2 (enExample)
BR (1) BRPI0916703A2 (enExample)
CA (1) CA2731499C (enExample)
CO (1) CO6341637A2 (enExample)
CY (1) CY1118200T1 (enExample)
DK (1) DK2315773T3 (enExample)
EA (1) EA024826B1 (enExample)
ES (1) ES2602430T3 (enExample)
HR (1) HRP20161458T1 (enExample)
HU (1) HUE031044T2 (enExample)
IL (1) IL210559A0 (enExample)
LT (1) LT2315773T (enExample)
MX (1) MX2011000983A (enExample)
PL (1) PL2315773T3 (enExample)
PT (1) PT2315773T (enExample)
SG (1) SG192456A1 (enExample)
SI (1) SI2315773T1 (enExample)
UA (1) UA107330C2 (enExample)
WO (1) WO2010010177A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6480999A (en) * 1998-11-04 2000-05-22 Isis Innovation Limited Tuberculosis diagnostic test
BRPI0916705A2 (pt) 2008-07-25 2015-11-10 Glaxo Group Ltd polipeptídeo isolado, polinucleotídeo isolado, composição farmacêutica, composição imunogênica, método para tratamento ou prevenção de tuberculose, e, usos de um polipeptídeo, e de um polinucleotídeo.
PT2315834T (pt) 2008-07-25 2018-08-10 Glaxosmithkline Biologicals Sa A proteína rv2386c de tuberculose, composições e as suas utilizações
EP2156945A1 (en) 2008-08-13 2010-02-24 Novelis Inc. Clad automotive sheet product
KR20170072366A (ko) 2009-04-24 2017-06-26 스태튼스 세룸 인스티튜트 재활성화를 예방하기 위한 결핵 백신
UA110103C2 (uk) 2010-01-27 2015-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Модифікований туберкульозний антиген
HUE039618T2 (hu) 2013-09-27 2019-01-28 Codexis Inc Enzimvariánsok automatizált szûrése
EP3049979B1 (en) * 2013-09-27 2020-01-01 Codexis, Inc. Structure based predictive modeling
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
MA55628A (fr) 2019-04-12 2022-02-16 C4 Therapeutics Inc Agents de dégradation tricycliques d'ikaros et d'aiolos
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
KR100797876B1 (ko) * 1998-04-07 2008-01-24 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
DE60139963D1 (de) * 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
WO2002054072A2 (en) * 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
US20040121322A9 (en) * 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
EP1781313A4 (en) * 2004-06-17 2009-08-26 Beckman Coulter Inc MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE
SI2457926T1 (sl) 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Nov postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis
CA2836319A1 (en) * 2005-06-23 2006-12-28 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
KR20170072366A (ko) * 2009-04-24 2017-06-26 스태튼스 세룸 인스티튜트 재활성화를 예방하기 위한 결핵 백신
UA110103C2 (uk) 2010-01-27 2015-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Модифікований туберкульозний антиген

Also Published As

Publication number Publication date
CA2731499A1 (en) 2010-01-28
HUE031044T2 (en) 2017-06-28
US20110117119A1 (en) 2011-05-19
IL210559A0 (en) 2011-03-31
AU2009273130B2 (en) 2014-10-16
HRP20161458T1 (hr) 2016-12-16
AU2009273130A1 (en) 2010-01-28
DK2315773T3 (en) 2016-12-12
US20140178423A1 (en) 2014-06-26
UA107330C2 (uk) 2014-12-25
CY1118200T1 (el) 2017-06-28
PL2315773T3 (pl) 2017-07-31
PT2315773T (pt) 2016-11-23
CN102164952A (zh) 2011-08-24
SG192456A1 (en) 2013-08-30
BRPI0916703A2 (pt) 2019-12-24
JP2011528895A (ja) 2011-12-01
CA2731499C (en) 2017-01-10
EP2315773A1 (en) 2011-05-04
CN102164952B (zh) 2016-05-25
MX2011000983A (es) 2011-03-02
SI2315773T1 (sl) 2016-12-30
CO6341637A2 (es) 2011-11-21
US9795663B2 (en) 2017-10-24
EP2315773B1 (en) 2016-08-24
WO2010010177A1 (en) 2010-01-28
KR20110044883A (ko) 2011-05-02
EA024826B1 (ru) 2016-10-31
EA201100072A1 (ru) 2011-10-31
ES2602430T3 (es) 2017-02-21
LT2315773T (lt) 2016-11-10

Similar Documents

Publication Publication Date Title
JP6104326B2 (ja) 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用
EP2315773B1 (en) Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis
JP5824360B2 (ja) 新規化合物および方法
WO2010010178A1 (en) The tuberculosis rv2707c protein, compositions and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140522

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160115

R150 Certificate of patent or registration of utility model

Ref document number: 5873332

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees